<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Abivax</strong> (NASDAQ:ABVX).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABVX, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 12 options trades for <strong>Abivax</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 41% bullish and 50%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $31,360, and 11, calls, for a total amount of $605,529.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $90.0 to $175.0 for Abivax during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Abivax's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Abivax's whale trades within a strike price range from $90.0 to $175.0 in the last 30 days. </p>
<h3>Abivax 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768413676_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="Options Call Chart" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1768413676_0.png"/></p>

<h3>Biggest Options Spotted:</h3>
<p></p><table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ABVX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.6</td>
<td>$5.5</td>
<td>$5.5</td>
<td>$125.00</td>
<td>$147.9K</td>
<td>533</td>
<td align="right">292</td>
</tr>
<tr>
<td>ABVX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/20/26</td>
<td>$17.0</td>
<td>$13.5</td>
<td>$15.0</td>
<td>$130.00</td>
<td>$108.0K</td>
<td>465</td>
<td align="right">100</td>
</tr>
<tr>
<td>ABVX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/20/26</td>
<td>$11.0</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$150.00</td>
<td>$88.0K</td>
<td>1.9K</td>
<td align="right">216</td>
</tr>
<tr>
<td>ABVX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$28.9</td>
<td>$25.5</td>
<td>$26.63</td>
<td>$110.00</td>
<td>$39.9K</td>
<td>10</td>
<td align="right">15</td>
</tr>
<tr>
<td>ABVX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$14.9</td>
<td>$13.4</td>
<td>$14.9</td>
<td>$110.00</td>
<td>$37.2K</td>
<td>1.1K</td>
<td align="right">173</td>
</tr>
</tbody>
</table><p></p>
<h3>About Abivax</h3>
<p>Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.</p>
<p>In light of the recent options history for Abivax, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Abivax</h3>
<ul>
<li>Currently trading with a volume of 1,013,271, the ABVX's price is up by 1.32%, now at $121.22. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 68 days.</li>
</ul>
<h3>Expert Opinions on Abivax</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $142.0.</p>
<ul>
<li>Maintaining their stance, an analyst from Citizens continues to hold a Market Outperform rating for Abivax, targeting a price of $131. </li>
<li>An analyst from BTIG persists with their Buy rating on Abivax, maintaining a target price of $150. </li>
<li>An analyst from Morgan Stanley has decided to maintain their Overweight rating on Abivax, which currently sits at a price target of $145. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics.</p>

ABVX

<p>Investors are taking a bearish stance on Abivax (NASDAQ:ABVX), with 50% of big-money traders showing bearish sentiment. Recent options activity revealed 12 trades, including 1 put worth $31,360 and 11 calls totaling $605,529. The expected price range for Abivax is between $90.0 and $175.0. Currently, ABVX is trading at $121.22, up 1.32%. Analysts have set an average price target of $142.0, with ratings ranging from Market Outperform to Buy, indicating potential for growth despite the bearish options sentiment.</p>

Abivax's Options: A Look at What the Big Money is Thinking